Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x L

Oncogene

Volumn 29, Issue 48, 2010, Pages 6367-6377

  Mayeenuddin, L H ^a,b   Yu, Y ^a,b   Kang, Z ^a,b   Helman, L J ^a   Cao, L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

apoptosis; Bcl 2; Bcl xL; IGF1R therapeutic antibody; predictive biomarker; tumor regression

Indexed keywords

CASPASE; CYTOCHROME C; MK 0646; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER REGRESSION; CARCINOGENESIS; CELL MEMBRANE DEPOLARIZATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; RHABDOMYOSARCOMA; SARCOMA CELL; SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; ANTIBODIES; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, IGF TYPE 1; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649846572     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.364     Document Type: Article

References (33)

1. Adams JM, Cory S. (2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337.
2. Barcia RN, Dana MR, Kazlauskas A. (2007). Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with bcl-xL. Am J Transplant 7: 2082-2089.
3. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS et al. (2003). A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63: 8912-8921.
4. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X et al. (2008). Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsive- ness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68: 8039-8048.
5. Clemmons DR. (2007). Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6: 821-833.
6. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE et al. (2005). Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073.
7. Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW et al. (2002). Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 3: 631-643.
8. Franken NA, Rodermond HM, Stap J, Haveman J, Van Bree C. (2006). Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319.
9. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF et al. (2005). A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113: 316-328.
10. Gualberto A, Pollak M. (2009). Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-3021.
11. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR et al. (2007). Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13: 5834-5840.
12. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
13. Jiang X, Wang X. (2004). Cytochrome C-mediated apoptosis. Annu Rev Biochem 73: 87-106.
14. Kooijman R. (2006). Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev 17: 305-323.
15. Kurmasheva RT, Houghton PJ. (2006). IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766: 1-22.
16. Manning BD, Cantley LC. (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
17. Minshall C, Arkins S, Straza J, Conners J, Dantzer R, Freund GG et al. (1997). IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors. J Immunol 159: 1225-1232.
18. Muslin AJ, Tanner JW, Allen PM, Shaw AS. (1996). Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84: 889-897.
19. Parrizas M, LeRoith D. (1997). Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138: 1355-1358.
20. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G et al. (1999). Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19: 7203-7215.
21. Phillips DC, Martin S, Doyle BT, Houghton JA. (2007). Sphingosine-induced apoptosis in rhabdomyosarcoma cell lines is dependent on pre-mitochondrial Bax activation and post-mitochondrial caspases. Cancer Res 67: 756-764.
22. Rathmell JC, Vander Heiden MG, Harris MH, Frauwirth KA, Thompson CB. (2000). In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell 6: 683-692.
23. Rodriguez-Tarduchy G, Collins MK, Garcia I, Lopez-Rivas A. (1992). Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol 149: 535-540.
24. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. (2003). A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63: 627-635.
25. Shimizu S, Narita M, Tsujimoto Y. (1999). Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochon-drial channel VDAC. Nature 399: 483-487.
26. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J et al. (2009). Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27: 5800-5807.
27. Troiano L, Ferraresi R, Lugli E, Nemes E, Roat E, Nasi M et al. (2007). Multiparametric analysis of cells with different mitochon-drial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2: 2719-2727.
28. Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M et al. (2005). Inhibition of insulin-like growth factor-I receptor (IGF1R) signaling and tumor cell growth by a fully human neutralizing anti-IGF1R antibody. Mol Cancer Ther 4: 1214-1221.
29. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL et al. (2005). In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and andro-gen-independent xenograft human prostate tumors. Clin Cancer Res 11: 3065-3074.
30. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H et al. (1997). The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91: 961-971.
31. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. (1995). Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291.
32. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628.
33. Zhang J, D'Ercole AJ. (2004). Expression of Mcl-1 in cerebellar granule neurons is regulated by IGF-I in a developmentally specific fashion. Brain Res Dev Brain Res 152: 255-263.